INTRODUCCIÓN: REVISIÓN CRITICA DEL PROBLEMA

CAPÍTULO VIII
265. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Seoane-Blanco A,
Moure-González M, Varela-Román A, Alvarez E, González-Juanatey JR. Evidence for a
role of advanced glycation end products in atrial fibrillation. Int J Cardiol. 2011 Jun 6.
266. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Moure-González M,
Seoane-Blanco A, Varela-Román A, Alvarez E, González-Juanatey JR. Advanced
glycation end-products: new markers of renal dysfunction in patients with chronic heart
failure. Med Clin (Barc). 2011 Apr 30;136(12):513-21..
267. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni
A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle
Heart Failure Model: prediction of survival in heart failure. Circulation. 2006 Mar
21;113(11):1424-33.
268. Mak S, Newton GE. The oxidative stress hypothesis of congestive heart failure: radical
thoughts. Chest. 2001 Dec;120(6):2035-46. Review.
269. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C Kislinger T, Stern DM,
Schmidt AM, De Caterina R. Advanced glycation and products activate endothelium
through signal-transduction receptor RAGE: a mechanism for amplification of
inflammatory responses. Circulation. 2002 Feb 19;105(7):816-22.
270. Zimmet JM, Hare JM. Nitroso-redox interactions in the cardiovascular system. Circulation.
2006 Oct 3;114(14):1531-44.
271. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling
danger to the vulnerable vasculature. Circ Res. 2010 Mar 19;106(5):842-53.
272. Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M,
Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T. Positive association between
serum levels of advanced glycation end products and the soluble form of receptor for
advanced glycation end products in nondiabetic subjects. Metabolism. 2006
Sep;55(9):1227-31.
273. Giamouzis G, Kalogeropoulos AP, Georgiopoulou VV, Agha SA, Rashad MA, Laskar SR,
Smith AL, Butler J. Incremental value of renal function in risk prediction with the Seattle
Heart Failure Model. Am Heart J. 2009 Feb;157(2):299-305.
274. May HT, Horne BD, Levy WC, Kfoury AG, Rasmusson KD, Linker DT, Mozaffarian D,
Anderson JL, Renlund DG. Validation of the Seattle Heart Failure Model in a communitybased
heart failure population and enhancement by adding B-type natriuretic peptide. Am
J Cardiol. 2007 Aug 15;100(4):697-700.
275. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation endproducts
(RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc
Dis Res. 2009 Jan;6(1):7-14.
276. Lapolla A, Reitano R, Seraglia R, Sartore G, Ragazzi E, Traldi P. Evaluation of advanced
glycation end products and carbonyl compounds in patients with different conditions of
oxidative stress. Mol Nutr Food Res. 2005 Jul;49(7):685-90.
277. Pfister R, Diedrichs H, Schiedermair A, Rosenkranz S, Hellmich M, Erdmann E, Schneider
CA. Prognostic impact of NT-proBNP and renal function in comparison to contemporary
multi-marker risk scores in heart failure patients. Eur J Heart Fail. 2008 Mar;10(3):315-20.
278. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced
glycation end products. Implications for induction of oxidant stress and cellular
dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994
Oct;14(10):1521-8.
279. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Yamasaki Y.
Endogenous secretory RAGE but not soluble RAGE is associated with carotid
atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res. 2008 Sep;5(3):190-7.
280. Van Heerebeek L, Paulus WJ. The dialogue between diabetes and diastole. Eur J Heart Fail.
2009 Jan;11(1):3-5.
240